Abstract Details

Title Physical Activity and Risk of Alzheimer Disease: Data from the NEDICES Cohort

Topic Aging and Dementia

Presentation(s) P03 - (-)

Poster/Presentation
Number 103

Objective

Background BACKGROUND: It has been described regular physical activity is a protective factor for AD and dementia.

Design/Methods DESIGN/METHODS: The NEDICES cohort is a population-based survey in the elderly, conducted from 1994 to 1995 (first wave), with a 3-year follow-up from 1997 to 1998 (second wave). The baseline survey screened 5,278 subjects and evaluated their general health status (500 items) including self-reports of intensity of physical activity. In the second wave all cases with incident dementia and AD were detected, diagnosed using DSM-IV and NINCDS-ADRDA criteria. The risk of incident dementia was assessed using Cox proportional hazards models.

Results RESULTS: The main data about dementia incidence have been reported (J Neurol Sci 2008; 264:63-72). 3,040 participants with baseline information about intensity of physical activity had a mean duration of follow-up of 3.2 years. Of the 115 AD incident cases, only 83 had adequate physical activity information in the first wave. The most inclusive Cox regression showed that age, education, and physical activity had clear significant statistical confiance in the AD incidence risk. The hazard ratio for regular physical activity was 0.93 (CI95% 0.87-0.99); p<0.02. Other possible risk or protective factors such as self reported health and others have less clear statistical confidence in Cox regressions.

Conclusions CONCLUSIONS: The NEDICES cohort data indicated that regular physical activity could represent a protective factor for AD in the elderly. Otherwise, physical inactivity might be a preclinical marker of dementia. More additional studies are required.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Zachary Simmons, MD, FAAN (Penn State Hershey Med Center)	Dr. Simmons has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Simmons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clene. Dr. Simmons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Insmed. Dr. Simmons has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Simmons has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Corcept. The institution of Dr. Simmons has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. The institution of Dr. Simmons has received research support from MGH. The institution of Dr. Simmons has received research support from Clene. The institution of Dr. Simmons has received research support from NIH via MGH. The institution of Dr. Simmons has received research support from Aburo. The institution of Dr. Simmons has received research support from NIH subaward via Univ of Pennsylvania.
Felix Bermejo-Pareja, MD	No disclosure on file
	No disclosure on file
Alvaro Sanchez (Fundacion Investigacion Biomedica Hospital 12)	No disclosure on file
	No disclosure on file
	No disclosure on file
Alberto Villarejo Galende	Alberto Villarejo Galende has nothing to disclose.
Julian Benito-Leon	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��